AR078818A1 - DERIVATIVES OF AZAINDOL - Google Patents

DERIVATIVES OF AZAINDOL

Info

Publication number
AR078818A1
AR078818A1 ARP100103979A ARP100103979A AR078818A1 AR 078818 A1 AR078818 A1 AR 078818A1 AR P100103979 A ARP100103979 A AR P100103979A AR P100103979 A ARP100103979 A AR P100103979A AR 078818 A1 AR078818 A1 AR 078818A1
Authority
AR
Argentina
Prior art keywords
alkyl
independently selected
alkoxy
cycloalkyl
aryl
Prior art date
Application number
ARP100103979A
Other languages
Spanish (es)
Inventor
David Michael Evans
Christine Elizabeth Allan
Original Assignee
Vantia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vantia Ltd filed Critical Vantia Ltd
Publication of AR078818A1 publication Critical patent/AR078818A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Abstract

Composiciones que comprenden dichos compuestos; el uso de dichos compuestos en terapia (tal como asma o EPOC); y métodos para tratar pacientes con tales compuestos. Reivindicacion 1: Un compuesto de formula (1) en donde R1 y R2 se seleccionan independientemente de H, hidroxilo, alquilo C1-10, alcoxi C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-10, heterocicloalquilo, arilo, heteroarilo, ariloalquilo C1-4 y heteroariloalquilo C1-4; R3 se selecciona de H, alquilo C1-10 y alquenilo C2-6; R4 y R5 se seleccionan independientemente de H y alquilo C1-6; A1 se selecciona de CR6 y S(O)R7; R6 se selecciona de R7 y los grupos de las formulas (2), (3) y (4); R7 se selecciona de alquilo C1-6, alquenilo C2-6, cicloalquilo C3-10, arilo, y ariloalquilo C1-4; R8 y R9 se seleccionan independientemente de H, alquilo C1-10, alquenilo C2-6, cicloalquilo C3-10, heterocicloalquilo, arilo, heteroarilo, ariloalquilo C1-4 y heteroariloalquilo C1-4; R10 y R11 se seleccionan independientemente de H, alquilo C1-10, alquenilo C2-6, cicloalquilo C3-10, heterocicloalquilo, arilo, heteroarilo, ariloalquilo C1-4, ariloalquenilo C2-4, heteroariloalquilo C1-4, -SO2alquilo C1-6, -SO2arilo y -SO2ariloalquilo C1-4; o R10 y R11 junto con el átomo de nitrogeno al que están unidos pueden formar un anillo de 4-7 miembros que contiene N, que contiene opcionalmente otro heteroátomo seleccionado de N, O y S, y opcionalmente sustituido con 1 o 2 sustituyentes independientemente seleccionados de alquilo C1-6, alcoxi C1-6, halo, CN e hidroxilo; dicho anillo que contiene N puede también estar opcionalmente fusionado a un grupo arilo; o R8 y R10 junto con los átomos a los que están unidos pueden formar un anillo saturado o parcialmente insaturado de 4-7 miembros que contiene N, que contiene opcionalmente otro heteroátomo seleccionado de N, O y S, y opcionalmente sustituido en el carbono con 1 o 2 sustituyentes independientemente seleccionados de alquilo C1-6, alcoxi C1-6, halo, CN e hidroxilo; o R9 está ausente y R8 y R10 junto con los átomos a los que están unidos pueden formar un anillo aromático mono o bicíclico de 5, 6, 9 o 10 miembros que contiene N, que contiene opcionalmente otro heteroátomo seleccionado de N, O y S, y opcionalmente sustituido en el carbono con 1, 2 o 3 sustituyentes independientemente seleccionados de alquilo C1-6, alcoxi C1-6, halo, CN, arilo, COOR15 e hidroxilo; o R8 y R10 juntos pueden formar un grupo de acuerdo con formula (5) o formula (6); R12 y R13 se seleccionan independientemente de H, alquilo C1-10, alquenilo C2-6, cicloalquilo C3-10, heterocicloalquilo, arilo, heteroarilo, ariloalquilo C1-4, ariloalquenilo C2-4, heteroariloalquilo C1-4, -SO2alquilo C1-6, -SO2arilo y SO2ariloalquilo C1-4; Ra y Rb se seleccionan independientemente de H, alquilo C1-10, alquenilo C2-6, cicloalquilo C3-10, heterocicloalquilo, arilo, heteroarilo, ariloalquilo C1-4, ariloalquenilo C2-4, heteroariloalquilo C1-4, -SO2alquilo C1-6, -SO2arilo y SO2ariloalquilo C1-4; o Ra y Rb junto con los átomos a los que están unidos pueden formar un anillo saturado o parcialmente insaturado de 4-7 miembros que contiene N, que contiene opcionalmente otro heteroátomo seleccionado de N, O y S, y opcionalmente sustituido con carbono con 1 o 2 sustituyentes independientemente seleccionados de alquilo C1-6, alcoxi C1-6, halo, CN e hidroxilo; dicho anillo que contiene N puede también estar opcionalmente fusionado a un grupo arilo; o Ra y Rb junto con los átomos a los que están unidos pueden formar un anillo aromático mono o bicíclico de 5, 6, 9 o 10 miembros que contiene N, que contiene opcionalmente otro heteroátomo seleccionado de N, O y S, y opcionalmente sustituido con carbono con 1, 2 o 3 sustituyentes independientemente seleccionados de alquilo C1-6, alcoxi C1-6, halo, CN, arilo, COOR15 e hidroxilo; R14 se selecciona de H, alquilo C1-6, alcoxi C1-6, OH, CN, CF3, COOR15, halo y NR15R16; R15 y R16 se seleccionan independientemente de H y alquilo C1-6; R17, R18 R19 y R20 se seleccionan independientemente de H, hidroxilo, halo, CN, alquilo C1-10 y alcoxi C1-6; f y g se seleccionan independientemente de 0, 1, 2 y 3, de manera tal que f+ g=1, 2 o 3; h se selecciona de 1 y 2; en donde: alquilo puede estar opcionalmente sustituido con 1 o 2 sustituyentes independientemente seleccionados de cicloalquilo C3-10, alcoxi C1-6, OH, CN, CF3, COOR15, fluoro y NR15R16; alquenilo puede estar opcionalmente sustituido con 1 o 2 sustituyentes independientemente seleccionados de cicloalquilo C3-10, alcoxi C1-6, OH, CN, CF3, COOR15, fluoro y NR15R16; alquinilo puede estar opcionalmente sustituido con 1 o 2 sustituyentes independientemente seleccionados de cicloalquilo C3-10, alcoxi C1-6, OH, CN, CF3, COOR11, fluoro y NR11R12; alcoxi puede estar opcionalmente sustituido con 1 o 2 sustituyentes independientemente seleccionados de cicloalquilo C3-10, OH, CN, CF3, COOR15, fluoro y NR15R16; cicloalquilo es un anillo hidrocarburo mono o bicíclico no aromático, opcionalmente fusionado a un grupo arilo, en donde dicho anillo cicloalquilo contiene opcionalmente, cuando es posible, hasta 2 enlaces dobles; y en donde, a menos que se especifique lo contrario, dicho cicloalquilo puede estar opcionalmente sustituido por 1 o 2 sustituyentes independientemente seleccionados de alquilo C1-6, alcoxi C1-6, OH, CN, CF3, COOR15, fluoro y NR15R16; heterocicloalquilo es un anillo mono o bicíclico, no aromático de 3 a 10 miembros unido a C o unido a N, en donde dicho anillo heterocicloalquilo contiene, cuando es posible, 1, 2 o 3 heteroátomos independientemente seleccionados de N, NR15, S(O)q y O; y dicho anillo heterocicloalquilo contiene opcionalmente, cuando es posible, 1 o 2 enlaces dobles, y está opcionalmente sustituido en el carbono con 1 o 2 sustituyentes independientemente seleccionados de alquilo C1-6, alcoxi C1-6, OH, CN, CF3, halo, COOR15, NR15R16 y arilo; arilo es un sistema de anillos aromático simple o fusionado que contiene de 6 o 10 átomos de carbono; en donde, a menos que se especifique lo contrario, cada aparicion de arilo puede estar opcionalmente sustituida con hasta 5 sustituyentes independientemente seleccionados de alquilo C1-6, alcoxi C1-6, OH, halo, CN, COOR15, CF3 y NR15R16; heteroarilo es un anillo aromático mono o bicíclico de 5, 6, 9 o 10 miembros, que contiene, cuando es posible, 1, 2 o 3 miembros del anillo independientemente seleccionados de N, NR15, S y O; en donde, a menos que se especifique lo contrario, dicho heteroarilo puede estar opcionalmente sustituido con 1, 2 o 3 sustituyentes independientemente seleccionados de alquilo C1-6, alcoxi C1-6, OH, halo, CN, COOR11, CF3 y NR15R16; q es 0, 1 o 2; y tautomeros, estereoisomeros, sales y solvatos farmacéuticamente aceptables del mismo.Compositions comprising said compounds; the use of said compounds in therapy (such as asthma or COPD); and methods to treat patients with such compounds. Claim 1: A compound of formula (1) wherein R1 and R2 are independently selected from H, hydroxy, C1-10 alkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, heterocycloalkyl, aryl, heteroaryl, arylC 1-4 alkyl and heteroarylC 1-4 alkyl; R3 is selected from H, C1-10 alkyl and C2-6 alkenyl; R4 and R5 are independently selected from H and C1-6 alkyl; A1 is selected from CR6 and S (O) R7; R6 is selected from R7 and the groups of the formulas (2), (3) and (4); R 7 is selected from C 1-6 alkyl, C 2-6 alkenyl, C 3-10 cycloalkyl, aryl, and C 1-4 arylalkyl; R8 and R9 are independently selected from H, C1-10 alkyl, C2-6 alkenyl, C3-10 cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-4 arylalkyl and C1-4 heteroarylalkyl; R10 and R11 are independently selected from H, C1-10 alkyl, C2-6 alkenyl, C3-10 cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-4 arylalkyl, C2-4 arylalkenyl, C1-4 heteroarylalkyl, C1-6 alkyl , -SO2aryl and -SO2-C1-4alkylalkyl; or R10 and R11 together with the nitrogen atom to which they are attached can form a 4-7 membered ring containing N, which optionally contains another heteroatom selected from N, O and S, and optionally substituted with 1 or 2 independently selected substituents C1-6 alkyl, C1-6 alkoxy, halo, CN and hydroxyl; said ring containing N may also be optionally fused to an aryl group; or R8 and R10 together with the atoms to which they are attached can form a 4-7 membered saturated or partially unsaturated ring containing N, optionally containing another heteroatom selected from N, O and S, and optionally substituted on the carbon with 1 or 2 substituents independently selected from C1-6 alkyl, C1-6 alkoxy, halo, CN and hydroxyl; or R9 is absent and R8 and R10 together with the atoms to which they are attached can form a mono, bicyclic aromatic ring of 5, 6, 9 or 10 members containing N, optionally containing another heteroatom selected from N, O and S , and optionally substituted on carbon with 1, 2 or 3 substituents independently selected from C1-6 alkyl, C1-6 alkoxy, halo, CN, aryl, COOR15 and hydroxyl; or R8 and R10 together can form a group according to formula (5) or formula (6); R12 and R13 are independently selected from H, C1-10 alkyl, C2-6 alkenyl, C3-10 cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-4 arylalkyl, C2-4 arylalkenyl, C1-4 heteroarylalkyl, C1-6 alkyl , -SO2aryl and SO2arylC 1-4 alkyl; Ra and Rb are independently selected from H, C1-10 alkyl, C2-6 alkenyl, C3-10 cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-4 arylalkyl, C2-4 arylalkenyl, C1-4 heteroarylalkyl, C1-6 alkyl , -SO2aryl and SO2arylC 1-4 alkyl; or Ra and Rb together with the atoms to which they are attached can form a 4-7 membered saturated or partially unsaturated ring containing N, optionally containing another heteroatom selected from N, O and S, and optionally substituted with carbon with 1 or 2 substituents independently selected from C1-6 alkyl, C1-6 alkoxy, halo, CN and hydroxyl; said ring containing N may also be optionally fused to an aryl group; or Ra and Rb together with the atoms to which they are attached can form a mono, bicyclic, 5, 6, 9 or 10-membered aromatic ring containing N, optionally containing another heteroatom selected from N, O and S, and optionally substituted with carbon with 1, 2 or 3 substituents independently selected from C1-6 alkyl, C1-6 alkoxy, halo, CN, aryl, COOR15 and hydroxyl; R14 is selected from H, C1-6 alkyl, C1-6 alkoxy, OH, CN, CF3, COOR15, halo and NR15R16; R15 and R16 are independently selected from H and C1-6 alkyl; R17, R18 R19 and R20 are independently selected from H, hydroxyl, halo, CN, C1-10 alkyl and C1-6 alkoxy; f and g are independently selected from 0, 1, 2 and 3, such that f + g = 1, 2 or 3; h is selected from 1 and 2; wherein: alkyl may be optionally substituted with 1 or 2 substituents independently selected from C3-10 cycloalkyl, C1-6 alkoxy, OH, CN, CF3, COOR15, fluoro and NR15R16; alkenyl may be optionally substituted with 1 or 2 substituents independently selected from C3-10 cycloalkyl, C1-6 alkoxy, OH, CN, CF3, COOR15, fluoro and NR15R16; alkynyl may be optionally substituted with 1 or 2 substituents independently selected from C3-10 cycloalkyl, C1-6 alkoxy, OH, CN, CF3, COOR11, fluoro and NR11R12; Alkoxy may be optionally substituted with 1 or 2 substituents independently selected from C3-10 cycloalkyl, OH, CN, CF3, COOR15, fluoro and NR15R16; cycloalkyl is a non-aromatic mono or bicyclic hydrocarbon ring, optionally fused to an aryl group, wherein said cycloalkyl ring optionally contains, when possible, up to 2 double bonds; and wherein, unless otherwise specified, said cycloalkyl may be optionally substituted by 1 or 2 substituents independently selected from C1-6 alkyl, C1-6 alkoxy, OH, CN, CF3, COOR15, fluoro and NR15R16; heterocycloalkyl is a mono or bicyclic, non-aromatic 3 to 10 membered ring attached to C or attached to N, wherein said heterocycloalkyl ring contains, when possible, 1, 2 or 3 heteroatoms independently selected from N, NR15, S (O ) q and O; and said heterocycloalkyl ring optionally contains, when possible, 1 or 2 double bonds, and is optionally substituted on the carbon with 1 or 2 substituents independently selected from C1-6 alkyl, C1-6 alkoxy, OH, CN, CF3, halo, COOR15, NR15R16 and aryl; aryl is a simple or fused aromatic ring system containing 6 or 10 carbon atoms; wherein, unless otherwise specified, each occurrence of aryl may be optionally substituted with up to 5 substituents independently selected from C1-6 alkyl, C1-6 alkoxy, OH, halo, CN, COOR15, CF3 and NR15R16; heteroaryl is a mono, bicyclic aromatic ring of 5, 6, 9 or 10 members, containing, when possible, 1, 2 or 3 ring members independently selected from N, NR15, S and O; wherein, unless otherwise specified, said heteroaryl may be optionally substituted with 1, 2 or 3 substituents independently selected from C1-6 alkyl, C1-6 alkoxy, OH, halo, CN, COOR11, CF3 and NR15R16; q is 0, 1 or 2; and pharmaceutically acceptable tautomers, stereoisomers, salts and solvates thereof.

ARP100103979A 2009-10-28 2010-10-28 DERIVATIVES OF AZAINDOL AR078818A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25561009P 2009-10-28 2009-10-28
GBGB0918924.2A GB0918924D0 (en) 2009-10-28 2009-10-28 Azaindole derivatives

Publications (1)

Publication Number Publication Date
AR078818A1 true AR078818A1 (en) 2011-12-07

Family

ID=41434816

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100103979A AR078818A1 (en) 2009-10-28 2010-10-28 DERIVATIVES OF AZAINDOL

Country Status (5)

Country Link
AR (1) AR078818A1 (en)
GB (1) GB0918924D0 (en)
TW (1) TW201120038A (en)
UY (1) UY32976A (en)
WO (1) WO2011051672A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9290485B2 (en) 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
US20220298138A1 (en) * 2019-08-21 2022-09-22 Kalvista Pharmaceuticals Limited Enzyme inhibitors

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0147716A3 (en) 1983-12-24 1987-10-28 ANT Nachrichtentechnik GmbH Method and apparatus for the encipherable transmission of a series of binary information signals with authenticity check
JPS6235216A (en) 1985-08-09 1987-02-16 Noritoshi Nakabachi Method and device for measuring thickness of heterogeneous material layer nondestructively
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
GR1001529B (en) 1990-09-07 1994-03-31 Elmuquimica Farm Sl Process for the obtainment of a new pregna-1,4-diene-3,20-dione -16-17-acetal-21 esters
GB9019558D0 (en) 1990-09-07 1990-10-24 Szelke Michael Enzyme inhibitors
WO1993018007A1 (en) 1992-03-13 1993-09-16 Tokyo Tanabe Company Limited Novel carbostyril derivative
SE9301911D0 (en) 1993-06-03 1993-06-03 Ab Astra NEW PEPTIDE DERIVATIVES
US5464820A (en) 1993-06-22 1995-11-07 The University Hospital Specific inhibitors of tissue kallikrein
GB9318637D0 (en) 1993-09-08 1993-10-27 Ferring Res Ltd Enzyme inhibitors
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
US6683115B2 (en) 1999-06-02 2004-01-27 Theravance, Inc. β2-adrenergic receptor agonists
OA11558A (en) 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
WO2001083462A1 (en) 2000-04-27 2001-11-08 Boehringer Ingelheim Pharma Kg Novel, slow-acting betamimetics, a method for their production and their use as medicaments
GB0015876D0 (en) 2000-06-28 2000-08-23 Novartis Ag Organic compounds
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
US7144908B2 (en) 2001-03-08 2006-12-05 Glaxo Group Limited Agonists of beta-adrenoceptors
ES2296923T3 (en) 2001-03-22 2008-05-01 Glaxo Group Limited FORMANILID DERIVATIVES AS AGONISTS OF THE BETA2 ADRENORRECEPTOR.
EP2042168B1 (en) 2001-09-14 2013-10-23 Glaxo Group Limited Inhalation formulation comprising phenethanolamine derivatives for the treatment of respiratory diseases
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
WO2003042160A1 (en) 2001-11-13 2003-05-22 Theravance, Inc. Aryl aniline beta-2 adrenergic receptor agonists
CA2470813A1 (en) 2001-12-20 2003-07-03 Bayer Healthcare Ag 1,4-dihydro-1,4-diphenylpyridine derivatives
GB0204719D0 (en) 2002-02-28 2002-04-17 Glaxo Group Ltd Medicinal compounds
GB0205527D0 (en) * 2002-03-08 2002-04-24 Ferring Bv Inhibitors
DE60318193T2 (en) 2002-04-25 2008-12-04 Glaxo Group Ltd., Greenford PHENETHANOLAMINDERIVATE
US6747043B2 (en) 2002-05-28 2004-06-08 Theravance, Inc. Alkoxy aryl β2 adrenergic receptor agonists
AU2003231865A1 (en) 2002-05-31 2003-12-19 Genzyme Corporation Alpha acyloxyacetamides for kallikrein and urokinase inhibition
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
PE20050130A1 (en) 2002-08-09 2005-03-29 Novartis Ag ORGANIC COMPOUNDS
GB0219896D0 (en) 2002-08-27 2002-10-02 Bayer Ag Dihydropyridine derivatives
WO2004020410A2 (en) 2002-08-27 2004-03-11 Bayer Healthcare Ag Dihydropyridinone derivatives as hne inhibitors
GB0220730D0 (en) 2002-09-06 2002-10-16 Glaxo Group Ltd Medicinal compounds
PL375647A1 (en) 2002-09-10 2005-12-12 Bayer Healthcare Ag Pyrimidinone derivatives as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes
US7566723B2 (en) 2002-09-10 2009-07-28 Bayer Healthcare Ag 1-phenyl1-3,4-dihydropyrimidin-2(1H)-one derivatives and their use
DE10246374A1 (en) 2002-10-04 2004-04-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg New 4-(2-alkylamino-1-hydroxyethyl)-3-alkoxy-benzene-1,2-diol derivatives, are beta-mimetics having a long duration of action, useful e.g. for treating asthma, chronic obstructive pulmonary disease or arrhythmia
CA2499314C (en) 2002-10-11 2010-08-24 Pfizer Inc. Indole derivatives as beta-2 agonists
EP1440966A1 (en) 2003-01-10 2004-07-28 Pfizer Limited Indole derivatives useful for the treatment of diseases
WO2004037807A2 (en) 2002-10-22 2004-05-06 Glaxo Group Limited Medicinal arylethanolamine compounds
GB0225030D0 (en) 2002-10-28 2002-12-04 Glaxo Group Ltd Medicinal compounds
RU2332400C2 (en) 2002-10-28 2008-08-27 Глаксо Груп Лимитед Phenethanolamine derivatives for treatment of respiratory diseases
GB0225540D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
GB0225535D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
JP2004161702A (en) 2002-11-14 2004-06-10 Hokko Chem Ind Co Ltd METHOD FOR PRODUCING gamma-JASMOLACTONE
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
DE10253282A1 (en) 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Treatment of chronic obstructive pulmonary disease, using new or known N-substituted 2-amino-1-(benz-(1,4)-oxazin-3-on-8-yl)-ethanol derivative beta-mimetic agents, suitable for once-daily administration
DE10253220A1 (en) 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg New 2-(N-phenylalkyl-amino)-1-phenyl-ethanol derivatives, are beta-adrenergic agents especially useful for treating inflammatory and obstructive respiratory diseases such as asthma or COPD
DE10258695A1 (en) 2002-12-16 2004-06-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg New 2-(2-hydroxy-2-(3-methylsulfonylamino-4-hydroxyphenyl)ethylamino-4-(pyrid-2-ylamino)-2-methylbutane used e.g. for treating asthma and chronic obstructive pulmonary disease
GB0303396D0 (en) 2003-02-14 2003-03-19 Glaxo Group Ltd Medicinal compounds
EP1460064A1 (en) 2003-03-14 2004-09-22 Pfizer Limited Indole-2-carboxamide derivatives useful as beta-2 agonists
JP4767842B2 (en) 2003-04-01 2011-09-07 セラヴァンス， インコーポレーテッド Diarylmethyl compounds and related compounds having β2 adrenergic receptor agonist activity and muscarinic receptor antagonist activity
MXPA05010712A (en) 2003-04-04 2005-12-15 Novartis Ag Quinoline-2-one-derivatives for the treatment of airways diseases.
US7268147B2 (en) 2003-05-15 2007-09-11 Pfizer Inc Compounds useful for the treatment of diseases
WO2004106333A1 (en) 2003-05-28 2004-12-09 Theravance, Inc. Azabicycloalkane compounds as muscarinic receptor antagonists
MXPA05013059A (en) 2003-06-04 2006-03-02 Pfizer 2-amino-pyridine derivatives as beta-2 adrenoreceptor agonists.
GB0312832D0 (en) 2003-06-04 2003-07-09 Pfizer Ltd 2-amino-pyridine derivatives useful for the treatment of diseases
SE0302324D0 (en) 2003-08-28 2003-08-28 Astrazeneca Ab Novel compounds
SE0302323D0 (en) 2003-08-28 2003-08-28 Astrazeneca Ab Novel compounds
SE0302486D0 (en) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
SE0302487D0 (en) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
WO2005033121A2 (en) 2003-10-03 2005-04-14 King Pharmaceuticals Research & Development, Inc. Synthesis of 2-aralkyloxyadenosines, 2-alkoxyadenosines, and their analogs
GB0323701D0 (en) 2003-10-09 2003-11-12 Glaxo Group Ltd Formulations
GB0324654D0 (en) 2003-10-22 2003-11-26 Glaxo Group Ltd Medicinal compounds
GB0324886D0 (en) 2003-10-24 2003-11-26 Glaxo Group Ltd Medicinal compounds
US20090246281A1 (en) 2003-11-03 2009-10-01 Norton Healthcare Ltd. Soft steroid compositions for use in dry powder inhalers
GB0328490D0 (en) 2003-12-09 2004-01-14 Glaxo Group Ltd Medicinal compounds
GB0329182D0 (en) 2003-12-17 2004-01-21 Glaxo Group Ltd Chemical compounds
US8241489B2 (en) 2003-12-19 2012-08-14 Shell Oil Company Systems, methods, and catalysts for producing a crude product
DE102004001413A1 (en) 2004-01-09 2005-08-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-hydroxymethyl-4-hydroxy-phenyl derivatives for the treatment of chronic obstructive pulmonary disease
TW200531692A (en) 2004-01-12 2005-10-01 Theravance Inc Aryl aniline derivatives as β2 adrenergic receptor agonists
CA2553293C (en) 2004-01-22 2010-12-14 Pfizer Inc. Sulfonamide derivatives for the treatment of diseases
RS50561B (en) 2004-01-22 2010-05-07 Pfizer Inc. Sulfonamide derivatives for the treatment of diseases
DE102004003428A1 (en) 2004-01-23 2005-08-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg New long-acting beta-2 agonists, and their use as pharmaceuticals
DE502005010170D1 (en) 2004-02-14 2010-10-14 Boehringer Ingelheim Pharma NEW LOW-ACTIVE BETA-2 AGONISTS AND THEIR USE AS DRUGS
US8097629B2 (en) 2004-02-19 2012-01-17 Bayer Pharma Aktiengesellschaft Dihydropyridinone derivatives
WO2005082863A2 (en) 2004-02-26 2005-09-09 Bayer Healthcare Ag 1,4 diaryl-dihydropyrimidin-2 ones and their use as a human neutrophil elastase inhibitors
JP4825194B2 (en) 2004-02-26 2011-11-30 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト 1,4-Diaryl-dihydropyrimidin-2-one compounds and their use as human neutrophil elastase inhibitors
WO2005092861A1 (en) 2004-03-11 2005-10-06 Pfizer Limited Quinolinone derivatives pharmaceutical compositions containing them and their use
EP1577306A1 (en) 2004-03-17 2005-09-21 Boehringer Ingelheim Pharma GmbH & Co.KG novel benzoxazinone derivatives as slow-acting betamimetics and use thereof in treatment of respiratory tract diseases
EP1577292A1 (en) 2004-03-17 2005-09-21 Pfizer Limited Phenylaminoethanol derivatives as beta2 receptor agonists
HN2004000023A (en) 2004-03-22 2007-11-23 Mars Inc ANIMAL MASCADURE
WO2005092841A1 (en) 2004-03-23 2005-10-06 Pfizer Limited Compounds having beta-agonist activity
PL1730103T3 (en) 2004-03-23 2010-10-29 Pfizer Formamide derivatives useful as adrenoceptor
CA2560368A1 (en) 2004-03-23 2005-10-06 Pfizer Inc. Compounds for the treatment of diseases
WO2005092860A1 (en) 2004-03-23 2005-10-06 Pfizer Limited Compounds for the treatment of diseases
EP1736465A4 (en) 2004-03-31 2009-06-17 Ajinomoto Kk Aniline derivatives
WO2005110990A1 (en) 2004-05-13 2005-11-24 Boehringer Ingelheim International Gmbh Hydroxy-substituted benzo-condensed heterocycles for use as beta agonists in the treatment of respiratory diseases
EP1595873A1 (en) 2004-05-13 2005-11-16 Boehringer Ingelheim Pharma GmbH & Co.KG Substituted cycloalkyl derivatives for the treatment of respiratory diseases
DE102004024454A1 (en) 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel enantiomerically pure beta agonists, process for their preparation and their use as pharmaceuticals
DE102004024451A1 (en) 2004-05-14 2005-12-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder formulations for inhalation containing enantiomerically pure beta agonists
CA2569395A1 (en) 2004-06-03 2005-12-22 Theravance, Inc. Diamine .beta.2 adrenergic receptor agonists
JP2008507532A (en) 2004-07-21 2008-03-13 セラヴァンス， インコーポレーテッド Diaryl ether β2 adrenergic receptor agonist
KR20070053237A (en) * 2004-07-27 2007-05-23 에스지엑스 파마슈티컬스, 인코포레이티드 Pyrrolo-pyridine kinase modulators
EP1807451A2 (en) 2004-08-03 2007-07-18 Dyax Corporation Hk1-binding proteins
WO2006016245A1 (en) 2004-08-05 2006-02-16 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
US7566785B2 (en) 2004-09-10 2009-07-28 Theravance, Inc. Amidine substituted aryl aniline compounds
DE102004045648A1 (en) 2004-09-21 2006-03-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg New betamimetics for the treatment of respiratory diseases
WO2006051373A1 (en) 2004-11-12 2006-05-18 Pfizer Limited Compounds for the treatment of diseases
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
WO2006065788A2 (en) * 2004-12-13 2006-06-22 Glaxo Group Limited Novel muscarinic acetylcholine receptor antagonists
US7625944B2 (en) 2006-07-31 2009-12-01 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein

Also Published As

Publication number Publication date
UY32976A (en) 2011-05-31
GB0918924D0 (en) 2009-12-16
WO2011051672A1 (en) 2011-05-05
TW201120038A (en) 2011-06-16

Similar Documents

Publication Publication Date Title
ES2564179T3 (en) Derivatives of 4- (p-quinonyl) -2-hydroxybutanamide for the treatment of mitochondrial diseases
AR084849A1 (en) DERIVATIVES OF OXAZINE AND ITS USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS
BR112015001502A2 (en) azaindazole or diazaindazole derivatives for pain management
CO6251251A2 (en) DERIVATIVES OF PIRAZINONA AND ITS USE IN THE TREATMENT OF PULMONARY DISEASES
AR085960A1 (en) 1,3-OXAZINES AS INHIBITORS OF THE BACE1 AND / OR THE BACE2
AR078157A1 (en) DERIVATIVES OF PIRAZOL- [4,5-D] PIRROLO [2,3-B] PYRIDINE INHIBITORS OF JAK 2 THYROSINQUINASES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEMSELVES AND USE OF THE SAME IN THE TREATMENT OF CANCER
AR061548A1 (en) 3-AMINOPIRROLIDINO-4-REPLACED LACTAMAS AS INHIBITORS OF DIPEPTIDILPEPTIDASA IV (DPP-IV), PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND THE USE OF THE SAME IN THE TREATMENT OF DIABETES II.
CO6321265A2 (en) COMPOUNDS OF 2-AMIDO-3-METHYL PIRROID PYRIMIDINONE PHENYL-REPLACED AS BACE-1 INHIBITORS COMPOSITIONS AND ITS USE
PE20142456A1 (en) OXAZOLIDIN-2-ONA COMPOUNDS AND USES OF THE SAME AS INHIBITORS OF PI3Ks
AR079226A1 (en) ESPIROINDOLINONA- PIRROLIDINAS, PREPARATION PROCESSES AND USE OF THE SAME FOR THE TREATMENT AND PROFILAXIS OF CANCER
UY29002A1 (en) NEW HIDANTOINE DERIVATIVES, PARASU PREPARATION PROCESSES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THERAPY
AR086357A1 (en) INDAZOL DERIVATIVES ACTIVE SUBSTITUTES AS QUINASE INHIBITORS
AR056886A1 (en) PIRROLOPIRIDINE COMPOUNDS REPLACED INHIBITORS OF KINASES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES IN THE TREATMENT OF CANCER
ECSP12012293A (en) CERTAIN AMINO-PYRIMIDINS, COMPOSITION OF THE SAME AND METHODS FOR THE USE OF THE SAME
AR088226A1 (en) HETEROCICLIC PIPERIDINIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE OF THE SAME FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
AR059328A1 (en) DERIVATIVES OF ANTRANILAMIDA-2-AMINO-HETEROARENO-CARBOXAMIDA, A PROCESS FOR THEIR OBTAINING, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THE USE OF THESE COMPOUNDS FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF CETP MEDIATION
AR070479A1 (en) FUSIONED HETEROCICLIC DERIVATIVE AND ITS USE
ECSP088114A (en) NEW DERIVATIVES OF 2-AZETIDINONE AND ITS USE AS CHOLESTEROL ABSORPTION INHIBITORS FOR HYPERLIPIDEMIA TREATMENT
AR071514A1 (en) AMINOPIRIDINE DERIVATIVES
AR069796A1 (en) DERIVATIVES OF BENCIMIDAZOL, REPLACED BY CARBOXYL OR HYDROXYL, PROCESS TO PREPARE THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
EA201490726A1 (en) PHARMACEUTICAL COMPOUNDS FOR USING CLOSTRIDIUM DIFFICILE INFECTION IN THERAPY
AR084152A1 (en) TRIAZOLOPIRIMIDINE COMPOUNDS AS INHIBITORS OF PDE10A, A PROCESS FOR THEIR OBTAINING, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE TREATMENT OF CNS DISEASES
CU20090048A7 (en) NEW DERIVATIVES OF DIOSMETINE, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
PE20151748A1 (en) BACE1 INHIBITORS
AR069306A1 (en) DERIVATIVES OF METHYL-BENCIMIDAZOL AS FARNESOID X RECEPTOR MODULATORS (FXR)

Legal Events

Date Code Title Description
FB Suspension of granting procedure